GB Virus C Coinfection in Advanced HIV Type-1 Disease is Associated with Low CCR5 and CXCR4 Surface Expression on CD4(+) T-cells
Overview
Microbiology
Authors
Affiliations
Background: Coinfection with the flavivirus GB virus C (GBV-C) is frequent in patients suffering from HIV type-1 (HIV-1) infection because of shared routes of transmission. GBV-C coinfection has been proposed to exert a beneficial influence on HIV-1 infection. In vitro studies demonstrated down-regulation of C-C chemokine receptor type 5 (CCR5) as a potential mechanism by which GBV-C modulates HIV-1 disease progression. We therefore studied surface expression of the two major HIV-1 coreceptors, CCR5 and CXC chemokine receptor type 4 (CXCR4), on CD4(+) and CD8(+) T-cells in 128 HIV-1-positive patients stratified with respect to their GBV-C status, immune function and highly active antiretroviral therapy (HAART) status in vivo.
Methods: GBV-C infection was studied in 128 HIV-1-infected patients by nested reverse transcriptase PCR. Fluorescence-activated cell sorting analysis was used to measure CCR5 and CXCR4 surface expression on CD4(+) and CD8(+) T-cells.
Results: GBV-C RNA replication was detected in 30% (38/128) of patients. In HIV-1-positive patients with advanced immunodeficiency, we found up-regulation of CCR5 surface expression on CD4(+) T-cells; however, in patients with GBV-C coinfection, no up-regulation of CCR5 CD4(+) T-cells was detected. Furthermore, CXCR4 surface expression was reduced in GBV-C-coinfected patients. These findings were independent of HAART status and HIV-1 viral load. HIV-1 coreceptor expression on CD8(+) T-cells was not altered in patients with GBV-C coinfection.
Conclusions: GBV-C coinfection in HIV-1 disease leads to reduced expression of the two major HIV-1 coreceptors, CCR5 and CXCR4, on CD4(+) T-cells in patients at an advanced stage of immunodeficiency, providing a possible molecular explanation for the clinical benefit of GBV-C coinfection in late-stage HIV-1 disease.
Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease?.
Stapleton J Front Immunol. 2022; 13:887760.
PMID: 35707535 PMC: 9190258. DOI: 10.3389/fimmu.2022.887760.
Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication.
Yu Y, Wan Z, Wang J, Yang X, Zhang C Virulence. 2022; 13(1):324-341.
PMID: 35132924 PMC: 8837232. DOI: 10.1080/21505594.2022.2029328.
Torimiro J, Mao Q, Wolfe N, Tamoufe U, Weil A, Mpoudi Ngole E Microbiol Res (Pavia). 2021; 4(1):1-4.
PMID: 34178297 PMC: 8232374. DOI: 10.4081/mr.2013.e1.
Farr Zuend C, Nomellini J, Smit J, Horwitz M J Virol. 2019; 93(18).
PMID: 31243127 PMC: 6714793. DOI: 10.1128/JVI.00614-19.
Human Pegivirus infection and lymphoma risk and prognosis: a North American study.
Fama A, Xiang J, Link B, Allmer C, Klinzman D, Feldman A Br J Haematol. 2018; 182(5):644-653.
PMID: 29808922 PMC: 6108902. DOI: 10.1111/bjh.15416.